The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
Open accessAbstract
Purpose: Panitumumab, a fully human antibody targeting the epidermal growth factor receptor, is active in patients with metastatic colorectal cancer (mCRC). This trial evaluated panitumumab added to bevacizumab and chemotherapy (oxaliplatin- and irinotecan-based) as first-line treatment for mCRC. Patients and Methods: Patients were randomly assigned within each chemotherapy cohort to bevacizumab and chemotherapy with or without panitumumab 6 mg/kg every 2 weeks. The primary end point was progression-free survival (PFS) within the oxaliplatin cohort. Tumor assessments were performed every 12 weeks and reviewed centrally. Results: A total of 823 and 230 patients were randomly assigned to the oxaliplatin and irinotecan cohorts, respectively. Panitumumab was discontinued after a planned interim analysis of 812 oxaliplatin patients showed worse efficacy in the panitumumab arm. In the final analysis, median PFS was 10.0 and 11.4 months for the panitumumab and control arms, respectively (HR, 1.27; 95% CI, 1.06 to 1.52); median survival was 19.4 months and 24.5 months for the panitumumab and control arms, respectively. Grade 3/4 adverse events in the oxaliplatin cohort (panitumumab v control) included skin toxicity (36% v 1%), diarrhea (24% v 13%), infections (19% v 10%), and pulmonary embolism (6% v 4%). Increased toxicity without evidence of improved efficacy was observed in the panitumumab arm of the irinotecan cohort. KRAS analyses showed adverse outcomes for the panitumumab arm in both wild-type and mutant groups. Conclusion: The addition of panitumumab to bevacizumab and oxaliplatin- or irinotecan-based chemotherapy results in increased toxicity and decreased PFS. These combinations are not recommended for the treatment of mCRC in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The PACCE study evaluated the addition of panitumumab to chemotherapy and bevacizumab, showing that the combined use of two biological agents may result in adverse outcomes irrespective of RAS mutation status [19].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Self-citationGiantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Self-citationVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Self-citationCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Cetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
Research works printed but not linked: 3
- Mitchell EP, 10th Annual World Congress of Gastrointestinal Cancers
- Van Cutsem E, 2007, J Clin Oncol, 25, 18s
- Ciardiello F, 2000, Clin Cancer Res, 6, 3739
Cited by
Sorted by citations
Items 501–600 of 849
The contribution of targeted therapy to the neoadjuvant chemoradiation of rectal cancer
Torino, F., Sarmiento, R., & Gasparini, G. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.02.002 · Cited by 9
Patient considerations in metastatic colorectal cancer – role of panitumumab
Rogers, J. E. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s115430 · Cited by 9
Young, K., Paz-Ares, L. G., Thatcher, N., Spigel, D. R., Shahidi, J., Soldatenkova, V., Grau, G., Kurek, R., & Shepherd, F. A. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.05.004 · Cited by 9
Self-citationElia, E. G., Städler, N., Ciani, O., Taylor, R. S., & Bujkiewicz, S. (2020) · Cancer Epidemiology · doi:10.1016/j.canep.2019.101665 · Cited by 9
Abdel-Rahman, O. M., & Ahmed, O. (2019) · International Journal of Colorectal Disease · doi:10.1007/s00384-019-03252-y · Cited by 9
Bibliometric analysis of randomized controlled trials of colorectal cancer over the last decade
Wang, C.-Y., Zhou, S., Li, X., Li, B., Zhang, J., Ge, Z., Zhang, Q., & Hu, J. (2020) · World Journal of Clinical Cases · doi:10.12998/wjcc.v8.i14.3021 · Cited by 9
Wanebo, H. J., & Berz, D. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21691 · Cited by 9
Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer
García-Sáenz, J. Á., Sastre, J., & Díaz‐Rubio, E. (2009) · Clinical & Translational Oncology · doi:10.1007/s12094-009-0436-5 · Cited by 10
Heskamp, S., Boerman, O. C., Molkenboer‐Kuenen, J. D. M., Sweep, F. C. G. J., Geurts-Moespot, A. J., Engelhardt, M. S., van der Graaf, W. T. A., Oyen, W. J. G., & van Laarhoven, H. W. M. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500460g · Cited by 9
Garrido‐Laguna, I., Patel, S. B., & Gill, D. M. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s68558 · Cited by 9
Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer
Matos, I. G., Élez, E., Capdevila, J., & Tabernero, J. M. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1220535 · Cited by 9
Cao, H., Guo, X., Zhu, X., Li, S.-S., & Zhen, Y. (2017) · Oncology Reports · doi:10.3892/or.2017.5606 · Cited by 9
Maintenance treatment in metastatic colorectal cancer: in search of the best strategy
Ron, D. A., Vera, R., Labandeira, C. M., Manrique, M. C. A., Núñez, M. Á., Cid, N. G., Mata, J. G., & Montés, A. F. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02267-9 · Cited by 9
Price, T. J., Tebbutt, N. C., Karapetis, C. S., Segelov, E., Pavlakis, N., Cunningham, D., Sobrero, A. F., Haller, D. G., & Shapiro, J. D. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.001 · Cited by 9
The Role of Targeted Therapy in the Treatment of Advanced Colorectal Cancer
Fakih, M. (2008) · Current Treatment Options in Oncology · doi:10.1007/s11864-009-0089-1 · Cited by 9
Spigel, D. R., Greco, F., Waterhouse, D. M., Shipley, D. L., Lane, C. M., Vázquez, E. R., Clark, B. L., Infante, J. R., Bendell, J. C., Burris, H. A., et al. (2010) · PubMed · Cited by 8
Self-citationOhhara, Y., Suenaga, M., Matsusaka, S., Shinozaki, E., Mizunuma, N., & Yamaguchi, T. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s77190 · Cited by 8
KRAS mutational analysis for colorectal cancerApplication: Pharmacogenomic
Wang, G., Kelley, R. K., & GAPPNet (2010) · PLoS Currents · doi:10.1371/currents.rrn1175 · Cited by 8
Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer
Rossi, L., Zoratto, F., Zullo, A., Papa, A., Zaccarelli, E., Giordani, E., Baiano, G., Colonna, M., Tomao, L., & Tomao, S. (2012) · OncoTargets and Therapy · doi:10.2147/ott.s30581 · Cited by 8
Ocean, A. J., Polite, B. N., Christos, P. J., Horvath, L. G., Hamilton, A. L., Matulich, D., Chen, H. X., Sparano, J. A., & Kindler, H. L. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.042 · Cited by 8
Burge, M., Semira, C., Lee, B., Lee, M., Kosmider, S., Wong, R., Shapiro, J. D., Ma, B. B. Y., Dean, A. P., Zimet, A. S., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.05.009 · Cited by 8
Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers
Gonzalez, N. S., Castet, F., Élez, E., Macarulla, T. M., & Tabernero, J. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1021772 · Cited by 9
Bzowska, M., Mężyk-Kopeć, R., Próchnicki, T., Kulesza, M., Klaus, T., & Bereta, J. (2013) · Acta Biochimica Polonica · doi:10.18388/abp.2013_1982 · Cited by 8
Pulmonary metastasis: rationale for local treatments and techniques
Nakajima, J. (2010) · General Thoracic and Cardiovascular Surgery · doi:10.1007/s11748-010-0609-8 · Cited by 8
Liver transplantation in treatment of colorectal liver metastases
Hagness, M. (2015) · Hepatic Oncology · doi:10.2217/hep.15.3 · Cited by 8
Soeda, H., Shimodaira, H., Watanabe, M., SUZUKI, T., Gamo, M., Takahashi, M., Komine, K., Kato, S., & Ishioka, C. (2014) · Molecular and Clinical Oncology · doi:10.3892/mco.2014.254 · Cited by 8
Integrating Systemic and Surgical Approaches to Treating Metastatic Colorectal Cancer
Mi, K., Kalady, M. F., Quintini, C., & Khorana, A. A. (2014) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2014.09.006 · Cited by 9
Loupakis, F., Cremolini, C., Fontanini, G., Stasi, I., Salvatore, L., & Falcone, A. (2009) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009348984 · Cited by 8
Price, T. J., Thavaneswaran, S., Burge, M., Segelov, E., Haller, D. G., Punt, C. J. A., Arnold, D., Karapetis, C. S., Tebbutt, N. C., Pavlakis, N., et al. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1170594 · Cited by 9
Karasic, T. B., Rosen, M. A., & O'Dwyer, P. J. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3389-3 · Cited by 8
McGregor, M., & Price, T. J. (2018) · Future Oncology · doi:10.2217/fon-2017-0711 · Cited by 8
Petracci, E., Scarpi, E., Passardi, A., Biggeri, A., Milandri, C., Vecchia, S., Gelsomino, F., Tassinari, D., Tamberi, S., Bernardini, I., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920937427 · Cited by 11
Novel Antineoplastics Targeting Genetic Changes in Colorectal Cancer
Joudeh, J., Allen, J. E., Das, A., Prabhu, V. V., Farbaniec, M., Adler, J. M., & El‐Deiry, W. S. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-6176-0_1 · Cited by 8
Optimizing the management of metastatic colorectal cancer
Comella, P., Casaretti, R., Avallone, A., & Franco, L. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.09.008 · Cited by 8
Evolving role of cetuximab in the treatment of colorectal cancer.
Schuch, G., Kobold, S., & Bokemeyer, C. (2009) · PubMed Central · Cited by 8
Cetuximab, chemotherapy and KRAS status in mCRC
Gill, S., & Goldberg, R. M. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.83 · Cited by 8
Tsujino, K., Shiraishi, J., Tsuji, T., Kurata, T., Kawaguchi, T., Kubo, A., & Takada, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp588 · Cited by 8
Clinical Practice Guidelines in Oncology TM
Engstrom, P. F., Arnoletti, J. P., Benson, A. B., Chen, Y., Choti, M. A., Cooper, H. S., Covey, A. M., Dilawari, R. A., Early, D. S., Enzinger, P. C., et al. (2009) · Cited by 8
Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting
Rolfo, C. D., Russo, A. D., Santini, D., Bronte, G., & Peeters, M. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.818135 · Cited by 8
Luan, W.-Y., Zhao, Q., Zhang, Z., Xu, Z.-X., Lin, S.-X., & Miao, Y. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i10.110661 · Cited by 9
Lockhart, C. (2009) · OncoTargets and Therapy · doi:10.2147/ott.s3849 · Cited by 7
Monoclonal antibodies and Fc fragments for treating solid tumors
Grau, S. J., & Eisenbeis (2012) · Biologics · doi:10.2147/btt.s19955 · Cited by 7
Translating Genomic Profiling to Gastrointestinal Cancer Treatment
Harada, K., Kaya, D. M., Shimodaira, Y., Song, S., Baba, H., & Ajani, J. A. (2017) · Future Oncology · doi:10.2217/fon-2016-0422 · Cited by 7
Molecular Genetics and the Role of Molecularly Targeted Agents in Metastatic Colorectal Carcinoma
Naeem, A., Tun, A. M., & Guevara, E. (2019) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-019-00272-3 · Cited by 7
Qi, W., Zhao, S., & Chen, J. (2020) · Future Oncology · doi:10.2217/fon-2020-0050 · Cited by 7
Antiangiogenic drugs: Chemosensitizers for combination cancer therapy
Donnini, S., Filippelli, A., Ciccone, V., Spini, A., Ristori, E., Ziche, M., & Morbidelli, L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90190-1.00008-1 · Cited by 7
Poad, H., Khan, S., Wheaton, L., Thomas, A., Sweeting, M. J., & Bujkiewicz, S. (2022) · Cancers · doi:10.3390/cancers14215391 · Cited by 7
Evolving role of cetuximab in the treatment of colorectal cancer
Schuch, G. (2009) · Cancer Management and Research · doi:10.2147/cmar.s4750 · Cited by 7
Review: Medical treatment of advanced colorectal cancer in 2009
Grothey, A. (2009) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009343302 · Cited by 7
Zheng, L., & Liang, R.-F. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s85178 · Cited by 7
Oliveira, S. C. R., Machado, K. K., Sabbaga, J., & Hoff, P. M. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181ddc7c4 · Cited by 7
Recent Advances in the Management of Stage IV Colon Cancer
Kanthan, R., Senger, J. B., Ahmed, S., & Kanthan, S. C. (2012) · Journal of Cancer Therapy · doi:10.4236/jct.2012.36145 · Cited by 7
Integrating Biomarkers Into Clinical Decision Making for Colorectal Cancer
Wilson, P. M., & Lenz, H. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.s.003 · Cited by 7
Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation
Rossi, L., Veltri, Zullo, A., Zoratto, F., Longo, Mottolese, Giannarelli, D., Ruco, Marchetti, Romiti, et al. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s43828 · Cited by 7
Panitumumab for the Treatment of Metastatic Colorectal Cancer: A Review
Prete, M. D., Giampieri, R., Faloppi, L., Bianconi, M., Bittoni, A., Andrikou, K., & Cascinu, S. (2015) · Immunotherapy · doi:10.2217/imt.15.46 · Cited by 7
Drug–diagnostic co-development: challenges and issues
Shimazawa, R., & Ikeda, M. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2016.1132163 · Cited by 7
Song, Q. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i14.4365 · Cited by 7
ACR Appropriateness Criteria® rectal cancer: metastatic disease at presentation.
Goodman, K. A., Milgrom, S. A., Herman, J. M., Abdel–Wahab, M., Azad, N. S., Blackstock, A. W., Das, P., Hong, T. S., Jabbour, S. K., Jones, W. E., et al. (2014) · PubMed · Cited by 7
Torres, O. J. M., Marques, M. C., Santos, F. N., de Farias, I. C., Coutinho, A. K., de Oliveira, C. V. C., Kalil, A. N., de Mello, C. A. L., Krüger, J. A. P., Fernandes, G. D. S., et al. (2016) · ABCD Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) · doi:10.1590/0102-6720201600030011 · Cited by 7
Qiu, T., Chen, W., Li, P., Sun, J., Gu, Y., & Chen, X. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s149110 · Cited by 7
A Comprehensive Review of Management of Colorectal Liver Mets in the Current Era.
Aziz, H., Ahmed, Z. A., Lee, Y., Drumm, G., & Saif, M. W. (2022) · PubMed · Cited by 7
Genetic Alterations in Colorectal Cancer in Older Patients
Saridaki, Z., & Souglakos, J. (2013) · Springer eBooks · doi:10.1007/978-0-85729-984-0_2 · Cited by 8
Neoadjuvant chemotherapy for non-/resectable metastases
Folprecht, G. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70147-2 · Cited by 7
A Methodological Approach to Personalized Therapies in Metastatic Cancer
Reichle, A., VOGT, T. M., & Hildebrandt, G. C. (2010) · Springer eBooks · doi:10.1007/978-90-481-9531-2_25 · Cited by 6
Usakova, V., SEVCIKOVA, K., USAK, J., Bartošová, Z., Mikulova, M., & Spanik, S. (2012) · Neoplasma · doi:10.4149/neo_2013_012 · Cited by 6
Batlle, J. F., Cuadrado‐Payán, E., de Castro, J., Caldés, T., Belda-Iniesta, C., Sastre, J., Barriuso, J., Marín, V. M., Díaz‐Rubio, E., & González-Barón, M. (2011) · Chemotherapy · doi:10.1159/000323624 · Cited by 6
Burris, H. A., Stephenson, J., Otterson, G. A., Stein, M. N., McGreivy, J. S., Sun, Y., Ingram, M., Ye, Y., & Schwartzberg, L. S. (2011) · Journal of Oncology · doi:10.1155/2011/853931 · Cited by 6
Duran, A. O., Karaca, H., Beşiroğlu, M., Bayoğlu, İ. V., Menekşe, S., Yapici, H. S., Yazılıtaş, D., Bahçeci, A., Uysal, M., Sevinç, A., et al. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.23.10375 · Cited by 6
The efficacy and safety of panitumumab supplementation for colorectal cancer
Wang, C., Tan, C.-Y., Chen, X., & Chen, S. (2020) · Medicine · doi:10.1097/md.0000000000019210 · Cited by 6
Interventions and Outcomes for Neoadjuvant Treatment of T4 Colon Cancer: A Scoping Review
Jung, F., Guidolin, K., Lee, M. H.-Y., Lam-Tin-Cheung, K., Zhao, G., Doshi, S., Chesney, T. R., Englesakis, M. F., Lukovic, J., O'Kane, G. M., et al. (2021) · Current Oncology · doi:10.3390/curroncol28030191 · Cited by 6
Dai, Wu, Shi, Y. X., Chen, C., & Xiao, X. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s41449 · Cited by 6
The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?
Lien, K., Berry, S. R., Ko, Y., & Chan, K. (2014) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2015.982100 · Cited by 6
Management and interpretation of novel toxicities of molecular targeted therapies: Renal toxicities
Carles, J., Morales‐Barrera, R., Pérez-García, J. M., Suárez, C., Rodon, J. A., & Valverde, C. M. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70045-0 · Cited by 6
Functions and Clinical Implications of Autocrine VEGF Signaling in Colorectal Cancer
Larsen, A. K., de Gramont, A., Poindessous, V., Bouygues, A., Ayadi, M., & Mésange, P. (2013) · Current Colorectal Cancer Reports · doi:10.1007/s11888-013-0177-2 · Cited by 7
Ocaña, A., Freedman, O. C., Amir, E., Šeruga, B., & Pandiella, A. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9451-7 · Cited by 6
Antiangiogenic Therapy in Colorectal Cancer: Where Are We 5 Years Later?
Jenab-Wolcott, J., & Giantonio, B. J. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.s.002 · Cited by 6
Rogowski, W., & Sulżyc‐Bielicka, V. (2016) · Współczesna Onkologia · doi:10.5114/wo.2016.61561 · Cited by 6
An appraisal of emerging second line therapies for metastatic colorectal cancer
Smolenschi, C., Perret, A., Dall'Armellina, F., Boige, V., Malka, D., Hollebecque, A., & Ducreux, M. P. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1840975 · Cited by 6
Zhao, C.-J., Li, S., & Liu, Q. (2015) · Journal of Chemotherapy · doi:10.1179/1973947815y.0000000049 · Cited by 6
Metabolic disorders associated with the use of targeted cancer therapies
Kotecki, N., Penel, N., & Awada, A. H. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000176 · Cited by 6
Lee, S. L., Dempsey‐Hibbert, N., Vimalachandran, D., Wardle, T. D., Sutton, P. A., & Williams, J. H. H. (2017) · Cell Stress and Chaperones · doi:10.1007/s12192-017-0774-0 · Cited by 6
Panitumumab in metastatic colorectal cancer
Hocking, C. M., Townsend, A. R., & Price, T. J. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2013.811064 · Cited by 6
What can the molecular pathologist offer for optimal decision making?
Richman, S. D., Hutchins, G. G. A., Seymour, M., & Quirke, P. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq379 · Cited by 7
Targeting the extracellular signature of metastatic colorectal cancers
Marchiò, S., Arap, W., & Pasqualini, R. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902762910 · Cited by 6
Li, C., Noonan, A. M., Hays, J. L., Roychowdhury, S., Malalur, P. G., Elkhatib, R. T., Manne, A., Mittra, A., Rahman, S., Yan, L., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3964 · Cited by 5
Optimizing the Efficacy of First-Line Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer
Li, S., & Chi, P. (2010) · BioDrugs · doi:10.2165/11584680-000000000-00000 · Cited by 5
Striking a balance between idealism and fatalism
Collingridge, D. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70225-x · Cited by 5
Metastatic colorectal cancer: treatment with panitumumab
Silvinato, A., Pedreira, I. D. S., dos Reis, J. C. B., Marcondes, J. G. Z., & Bernardo, W. M. (2018) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.64.07.568 · Cited by 5
Schaeybroeck, S. V., Lawler, M., Johnston, B. T., Salto‐Tellez, M., Lee, J., Loughlin, P., Wilson, R. H., & Johnston, P. G. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00077-1 · Cited by 5
Heterogeneous entity representation for medicinal synergy prediction
Wu, J., Wen, J., Yan, M., Dong, A., Gao, S., Wang, R., & Chen, C. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae750 · Cited by 5
Tolérance rénale des thérapies ciblées
Thariat, J., Janus, N., Barrière, J., & Launay‐Vacher, V. (2012) · Bulletin du Cancer · doi:10.1684/bdc.2011.1490 · Cited by 5
Integration of Anti-Epidermal Growth Factor Receptor Therapies With Cytotoxic Chemotherapy
Serrano, C., Markman, B., & Tabernero, J. M. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181e07670 · Cited by 5
Antiangiogenic Therapy of Colorectal Cancer: State of the Art, Challenges and New Approaches
Sarmiento, R., Longo, R., & Gasparini, G. (2012) · The International Journal of Biological Markers · doi:10.5301/jbm.2012.10441 · Cited by 5
Hayashi, K., Mitani, S., Taniguchi, H., Yasui, H., Muro, K., Mori, K. P., Gotoda, T., & Yamazaki, K. (2018) · Oncology · doi:10.1159/000493321 · Cited by 5
Hénaine, A. M., Chahine, G. Y., Massoud, M., Salameh, P., Awada, S., Lahoud, N., Elias, E. J., Salem, M., Ballout, S., Hartmann, D. J., et al. (2018) · Eastern Mediterranean Health Journal · doi:10.26719/emhj.18.063 · Cited by 5
Yin, J., Dawood, S. S., Cohen, R., Meyers, J., Zalcberg, J. R., Yoshino, T., Seymour, M., Maughan, T., Saltz, L. B., Cutsem, E. V., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211020547 · Cited by 5
Self-citationCardone, C., Martinelli, E., Troiani, T., Sforza, V., Avallone, A., Nappi, A. G., Montesarchio, V., Andreozzi, F., Biglietto, M., Calabrese, F., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000519 · Cited by 5
Lau, D. K., Burge, M., Roy, A. C., Chau, I., Haller, D. G., Shapiro, J. D., Peeters, M., Pavlakis, N., Karapetis, C. S., Tebbutt, N. C., et al. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1744439 · Cited by 5
Liu, S. V., Gollard, R., & Iqbal, S. (2012) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2012.01343.x · Cited by 5
Fojo, T., & Grady, C. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq247 · Cited by 5
Metadata
- Authors
- Hecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., Marshall, J., Cohn, A., McCollum, D., Stella, P., Deeter, R., Shahin, S., & Amado, R. G.
- Affiliations
- Amgen (United States) (US)
- Venue
- Journal of Clinical Oncology
- Published
- 2009-02-10
- Volume
- 27
- Issue
- 5
- Pages
- 672-680
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2002226820
- Cited by
- 850
- References
- 30
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 19 · 2023: 10 · 2022: 21 · 2021: 15 · 2020: 29 · 2019: 29 · 2018: 26 · 2017: 38 · 2016: 44 · 2015: 57 · 2014: 56 · 2013: 88 · 2012: 101
- FWCI
- 53.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- metastatic colorectal cancer, panitumumab, bevacizumab, oxaliplatin, irinotecan, EGFR inhibition, first-line chemotherapy, progression-free survival, treatment toxicity, KRAS mutation, anti-EGFR monoclonal antibody
- MeSH terms
- Bevacizumab, Irinotecan, Oxaliplatin, Panitumumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Organoplatinum Compounds, Colorectal Neoplasms, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
